Regeneron Pharmaceuticals Inc. share price logo

Regeneron Pharmaceuticals Inc.

NASDAQ: REGN

Large Cap

$763.98

+1.35

(+0.18%)

Live

as on

Regeneron Pharmaceuticals Inc. Stock Performance

as on August 4, 2026 at 1:08 am IST

  • Day's Low

    Day's High

    $759.25
    $771.95
    downward going graph

    0.62%

    Downside

    1.04%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $541.00
    $821.11
    downward going graph

    29.19%

    Downside

    7.48%

    Upside

    downward going graph

Regeneron Pharmaceuticals Inc. share price movements today

Previous Close
$762.63
Open
$770.09
Volume
65.2K
Day's Low - High
$759.25 - $771.95
52 Week Low - High
$541.00 - $821.11

Regeneron Pharmaceuticals Inc. Historical Returns

1 Month Return
+ 16.56 %
3 Month Return
+ 8.73 %
1 Year Return
+ 36.46 %
3 Year Return
-1.14 %
5 Year Return
+ 30.03 %

Regeneron Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Regeneron Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$78.5B

EPS (TTM)

52.5993

Dividend Yield

0.49%

Quarterly Earnings Growth YOY

-0.04%

PE Ratio (TTM)

18.87

Industry PE ratio

4.805185185185185

PEG Ratio

1.3436

EBITDA

4.7B

Revenue (TTM)

15.5B

Profit Margin

27.87%

Return On Equity TTM

14.04%

Regeneron Pharmaceuticals Inc. Stock Valuation

Track how Regeneron Pharmaceuticals Inc. P/E has moved over time to understand its valuation trends.

Regeneron Pharmaceuticals Inc. in the last 5 years

  • Overview

  • Trends

Lowest (8.22x)

December 31, 2021

Industry (4.81x)

August 3, 2026

Today (18.87x)

August 3, 2026

Highest (24.50x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 18.87x

Regeneron Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Regeneron Pharmaceuticals Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$78.5B30.03%18.8727.87%0.49%
BUY$39.9B535.48%NA0.00%NA
BUY$121.1B138.49%28.3335.51%NA

Stock Returns calculator for Regeneron Pharmaceuticals Inc. Stock including INR - Dollar returns

The Regeneron Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Regeneron Pharmaceuticals Inc. investment value today

Current value as on today

₹1,48,636

Returns

₹48,636

(+48.64%)

Returns from Regeneron Pharmaceuticals Inc. Stock

₹36,701 (+36.7%)

Dollar Impact

₹11,935 (+11.93%)

Analyst Recommendation on Regeneron Pharmaceuticals Inc. Stock

Based on 34 analysts

BUY

76.47%

Buy

20.59%

Hold

2.94%

Sell

Based on 34 analysts, 76.47% of analysts recommend a 'BUY' rating for Regeneron Pharmaceuticals Inc.. Average target price of $833.54

Regeneron Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Regeneron Pharmaceuticals Inc..

What analysts predicted

8.35%UPSIDE

Target Price

$833.54

Current Price

$763.98

Analyzed by

34 Analysts

Target

$833.54

Regeneron Pharmaceuticals Inc. target price $833.54, a slight upside of 8.35% compared to current price of $763.98. According to 34 analysts rating.

Indian Investors' Interest in Regeneron Pharmaceuticals Inc. Stock

Investment in Regeneron Pharmaceuticals Inc. Shares on INDmoney has grown by 129.62% in the last 30 days, indicating increased investment activity.

Time period: to

Change:129.62% versus previous 30 day period

Search interest for Regeneron Pharmaceuticals Inc. Stock has increased by 13% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:13% versus previous 30 day period

Regeneron Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3,145
3,547
3,720
3,789
3,028
3,675
3,754
3,884
3,605
4,290
Gross Profit
2,711
3,066
3,229
3,223
2,564
3,145
3,232
3,299
2,936
3,714
Operating Income
751
1,069
1,179
990
591
1,079
1,026
879
642
1,420
EBITDA
830
1,763
1,628
1,095
1,040
1,657
1,919
1,200
967
1,543
Interest Expense
16
14
13
10
8
3
19
12
12
11
Depreciation
114
120
121
126
126
135
136
145
123
123
Income Before Tax
700
1,628
1,493
958
905
1,518
1,763
1,043
831
1,527
Income Tax Expense
-21
195
152
40
96
127
303
199
104
230
Net Income
722
1,432
1,340
917
808
1,391
1,460
844
727
1,296
Net Profit Margin
22.96%
40.38%
36.03%
24.22%
26.70%
37.86%
38.89%
21.74%
20.17%
30.23%

Regeneron Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4,860
5,872
6,710
7,863
8,497
16,071
12,172
13,117
14,202
14,342
Gross Profit
4,560
5,475
6,276
7,081
7,141
13,348
10,467
12,233
12,231
12,242
Operating Income
1,330
2,079
2,534
2,209
3,576
8,946
5,385
4,047
3,990
3,577
EBITDA
1,435
2,225
2,682
2,420
4,103
9,669
5,259
4,047
5,318
5,818
Interest Expense
7
25
28
30
56
57
59
73
55
43
Depreciation
-
145
148
210
235
286
341
408
482
543
Income Before Tax
1,329
2,078
2,553
2,429
3,810
9,325
4,858
4,199
4,779
5,230
Income Tax Expense
434
880
109
313
297
1,250
520
245
367
725
Net Income
895
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
4,504
Net Profit Margin
18.42%
20.41%
36.42%
26.91%
41.35%
50.25%
35.64%
30.14%
31.07%
31.41%

Regeneron Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
1,432
1,340
917
808
1,391
1,460
844
727
1,296
Operating Cash Flow
354
1,291
1,262
1,045
1,144
1,618
1,170
1,078
574
Investing Cash Flow
-557
-574
350
647
-1,094
-402
220
-428
-92
Financing Cash Flow
-478
-634
-1,135
-1,089
-1,128
-717
-780
-802
-2,344
Change in Cash
-681
83
477
604
-1,077
497
610
-153
-1,863

Regeneron Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
4,504
Operating Cash Flow
1,307
2,195
2,430
2,618
7,081
5,014
4,594
4,420
4,978
Investing Cash Flow
-1,005
-1,463
-2,027
-70
-5,384
-3,784
-3,185
-2,468
-629
Financing Cash Flow
-24
-77
-252
-1,970
-1,005
-1,009
-1,790
-2,200
-3,715
Change in Cash
277
655
150
577
690
221
-381
-248
634

Mutual Funds that own Regeneron Pharmaceuticals Inc. Stock

Check out the Mutual Funds with significant holdings in Regeneron Pharmaceuticals Inc..

Global Institutional Holdings in Regeneron Pharmaceuticals Inc.

Funds
Holdings
Vanguard Portfolio Management, LLC
1.64%
Morgan Stanley - Brokerage Accounts
1.26%
T. Rowe Price Associates, Inc.
2.08%
Wellington Management Company LLP
1.75%
AQR Capital Management LLC
1.17%

Regeneron Pharmaceuticals Inc. News & Key Events

  • img

    Today's Timeline - 31 July

    Fri, 09:36 AM

    -

    Regeneron reports strong Q2 2026 growth, productive talks with Sanofi to expand collaboration on Dupixent follow-on programs.

Insights on Regeneron Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Regeneron Pharmaceuticals, Inc. has shown strong financial performance, with its net profit increasing for the last two quarters. It rose from $727.20 million to $1.29 billion, demonstrating an average increase of 43.9% each quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Regeneron Pharmaceuticals has shown strong revenue growth over the last two quarters. The revenue increased from $3.60 billion to $4.29 billion, reflecting an average increase of 16.0% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, REGN stock has moved up by 14.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 412.0% return, outperforming this stock by 375.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 488.1% return, outperforming this stock by 489.2%

About Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
OrganisationRegeneron Pharmaceuticals Inc.
Headquarters777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
IndustryBiotechnology
CEODr. Leonard S. Schleifer M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Regeneron Pharmaceuticals Inc.

Name

Title

Dr. Leonard S. Schleifer M.D., Ph.D.

Co-Founder, President, CEO & Co-Chairman

Dr. George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Mr. Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Ms. Melissa Lozner

Senior VP & Chief Compliance Officer

Mr. Christopher R. Fenimore CPA

Executive VP of Finance & CFO

Mr. Joseph J. LaRosa J.D.

Executive VP, General Counsel & Secretary

Dr. Andrew J. Murphy Ph.D.

Executive VP of Research & Co-Chief Scientific Officer

Mr. Daniel P. Van Plew

Executive VP and GM of Industrial Operations & Product Supply

Mr. Rajesh Ahuja

Senior Vice President of Quality Assurance & Operations

Mr. Ryan Steinberger

Executive VP, Chief Digital & Technology Officer

FAQs

What is Regeneron Pharmaceuticals Inc. share price today?

Regeneron Pharmaceuticals Inc. share price today is $763.98 as on . Regeneron Pharmaceuticals Inc. share today touched a day high of $771.95 and a low of $759.25.

What is the 52 week high and 52 week low for Regeneron Pharmaceuticals Inc. share?

Regeneron Pharmaceuticals Inc. share touched a 52 week high of $821.11 on and a 52 week low of $541.00 on . Regeneron Pharmaceuticals Inc. stock price today i.e. is trending at $763.98,which is 6.96% down from its 52 week high and 41.22% up from its 52 week low.

What is Regeneron Pharmaceuticals Inc.'s market capitalisation today?

Regeneron Pharmaceuticals Inc. market capitalisation is $0.08T as on .

How to invest in Regeneron Pharmaceuticals Inc. Stock (REGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Regeneron Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Regeneron Pharmaceuticals Inc. Shares that will get you 0.0020 shares as per Regeneron Pharmaceuticals Inc. share price of $763.98 per share as on August 3, 2026 at 7:38 pm IST.

What is the minimum amount required to buy Regeneron Pharmaceuticals Inc. Stock (REGN) from India?

Indian investors can start investing in Regeneron Pharmaceuticals Inc. (REGN) shares with as little as ₹95.335 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.35 in Regeneron Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Regeneron Pharmaceuticals Inc. share’s latest price of $763.98 as on August 3, 2026 at 7:38 pm IST, you will get 0.0131 shares of Regeneron Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Regeneron Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Regeneron Pharmaceuticals Inc. stock has given 30.03% share price returns and 28.47% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?